Value of 18F-fluorodeoxyglucose PET/CT imaging combined with serum carbohydrate antigen 125 and human epididymis protein 4 detection in diagnosis of ovarian malignancy
F-FDG) PET/CT imaging combined with serum carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) detection in the diagnosis of ovarian malignancy.
Methods:
A retrospective study was performed in 51 cases of malignant ovarian tumor and 17 cases of benign ovarian tumor
who received
18
F-FDG PET/CT imaging as well as serum CA125 and HE4 detection within a week.
Results:
The median maximum standardized uptake value (SUV
max
) in the malignant group
whose PET/CT imaging showed high uptake of
18
F-FDG locally
was significantly higher than that in the benign group (10.30
vs.
2.20
P
0.001). The median serum levels of CA125 and HE4 in the malignant group were significantly higher than that in the benign group (979.30 U/ml
vs
. 19.60 U/ml
and 490.30 pmol/L
vs
. 64.80 pmol/L
P
0.001). The diagnostic sensitivity
specificity
positive predictive value
negative predictive value and accuracy of PET/CT imaging combined with serum CA125 and HE4 detection were 84.3%
94.1%
97.7%
66.7% and 86.8%
respectively. The areas under receiver operating characteristic curve (ROC AUC) of PET/CT
CA125
HE4 and PET/CT combined with CA125 and HE4 were 0.8510.066
0.9270.032
0.9430.030 and 0.9580.024 (
P
0.001)
respectively.
Conclusion:
18
F-FDG PET/CT imaging combined with serum CA125 and HE4 detection has clinical diagnostic value with high sensitivity and specificity.